142 related articles for article (PubMed ID: 16283430)
1. Inhibitory mechanisms of low concentrations of oxidized low-density lipoprotein on platelet aggregation.
Chou DS; Chan CH; Hsiao G; Shen MY; Tsai YJ; Chen TF; Sheu JR
J Biomed Sci; 2006 May; 13(3):333-43. PubMed ID: 16283430
[TBL] [Abstract][Full Text] [Related]
2. alpha-Naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospholipase C activity and stimulation of cyclic GMP formation.
Hsiao G; Chang CY; Shen MY; Chou DS; Tzeng SH; Chen TF; Sheu JR
J Agric Food Chem; 2005 Jun; 53(13):5179-86. PubMed ID: 15969494
[TBL] [Abstract][Full Text] [Related]
3. C-phycocyanin, a very potent and novel platelet aggregation inhibitor from Spirulina platensis.
Hsiao G; Chou PH; Shen MY; Chou DS; Lin CH; Sheu JR
J Agric Food Chem; 2005 Oct; 53(20):7734-40. PubMed ID: 16190625
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory mechanisms of activated matrix metalloproteinase-9 on platelet activation.
Lee YM; Lee JJ; Shen MY; Hsiao G; Sheu JR
Eur J Pharmacol; 2006 May; 537(1-3):52-8. PubMed ID: 16624282
[TBL] [Abstract][Full Text] [Related]
5. Protective mechanisms of inosine in platelet activation and cerebral ischemic damage.
Hsiao G; Lin KH; Chang Y; Chen TL; Tzu NH; Chou DS; Sheu JR
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1998-2004. PubMed ID: 15976325
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation.
Hsiao G; Wang Y; Tzu NH; Fong TH; Shen MY; Lin KH; Chou DS; Sheu JR
J Lab Clin Med; 2005 Oct; 146(4):216-26. PubMed ID: 16194683
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets.
Sheu JR; Hsiao G; Chou PH; Shen MY; Chou DS
J Agric Food Chem; 2004 Jul; 52(14):4414-8. PubMed ID: 15237945
[TBL] [Abstract][Full Text] [Related]
8. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase C gamma 2-protein kinase C-p38 MAPK cascade.
Lin KH; Chang YF; Fan CY; Jayakumar T; Lee JJ; Chou DS; Hsiao G; Sheu JR
Transl Res; 2010 Feb; 155(2):97-108. PubMed ID: 20129490
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of antiplatelet and antithrombotic activity of midazolam in in vitro and in vivo studies.
Hsiao G; Shen MY; Chou DS; Chang Y; Lee LW; Lin CH; Sheu JR
Eur J Pharmacol; 2004 Mar; 487(1-3):159-66. PubMed ID: 15033388
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets.
Sheu JR; Lee CR; Lin CH; Hsiao G; Ko WC; Chen YC; Yen MH
Thromb Haemost; 2000 May; 83(5):777-84. PubMed ID: 10823277
[TBL] [Abstract][Full Text] [Related]
12. Potent antiplatelet activity of sesamol in an in vitro and in vivo model: pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase.
Chang CC; Lu WJ; Chiang CW; Jayakumar T; Ong ET; Hsiao G; Fong TH; Chou DS; Sheu JR
J Nutr Biochem; 2010 Dec; 21(12):1214-21. PubMed ID: 20015631
[TBL] [Abstract][Full Text] [Related]
13. Effect of oxidation on the platelet-activating properties of low-density lipoprotein.
Korporaal SJ; Gorter G; van Rijn HJ; Akkerman JW
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):867-72. PubMed ID: 15692097
[TBL] [Abstract][Full Text] [Related]
14. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents.
Russo I; Doronzo G; Mattiello L; De Salve A; Trovati M; Anfossi G
Thromb Res; 2004; 114(4):265-73. PubMed ID: 15381390
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies.
Sheu JR; Fong TH; Liu CM; Shen MY; Chen TL; Chang Y; Lu MS; Hsiao G
Br J Pharmacol; 2004 Sep; 143(1):193-201. PubMed ID: 15289295
[TBL] [Abstract][Full Text] [Related]
16. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
17. Regulation of VASP serine 157 phosphorylation in human neutrophils after stimulation by a chemoattractant.
Eckert RE; Jones SL
J Leukoc Biol; 2007 Nov; 82(5):1311-21. PubMed ID: 17684042
[TBL] [Abstract][Full Text] [Related]
18. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
19. Low concentration of oxidized low density lipoprotein suppresses platelet reactivity in vitro: an intracellular study.
Chou DS; Hsiao G; Shen MY; Fong TH; Lin CH; Chen TF; Sheu JR
Lipids; 2004 May; 39(5):433-40. PubMed ID: 15506238
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms involved in the antiplatelet activity of ketamine in human platelets.
Chang Y; Chen TL; Wu GJ; Hsiao G; Shen MY; Lin KH; Chou DS; Lin CH; Sheu JR
J Biomed Sci; 2004; 11(6):764-72. PubMed ID: 15591773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
